AVTX
Avalo Therapeutics (AVTX)
$
18About Avalo Therapeutics (AVTX)
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Details
Daily high
$8.20
Daily low
$7.79
Price at open
$8.14
52 Week High
$34.46
52 Week Low
$4.18
Market cap
85.6M
Dividend yield
0.00%
Volume
22,978
Avg. volume
64,497
P/E ratio
-.05
Avalo Therapeutics News
Details
Daily high
$8.20
Daily low
$7.79
Price at open
$8.14
52 Week High
$34.46
52 Week Low
$4.18
Market cap
85.6M
Dividend yield
0.00%
Volume
22,978
Avg. volume
64,497
P/E ratio
-.05